To be continued today… Valneva –

(AOF) – Valneva, a company specializing in vaccines, confirms the signing of the amendment to its advance purchase agreement with the European Commission, as announced by the company on July 20, 20222, the period during which member states could exercise their right of withdrawal having expired. Under this amendment, purchases of VLA2001, Valneva’s inactivated whole virus vaccine against Covid-19, by Member States consistent in 1.25 million doses of VLA2001 in 2022, with the option to purchase an identical quantity later this year for delivery in 2022.

The company plans to deliver the first doses of the vaccine to participating member states (Germany, Austria, Denmark, Finland and Bulgaria) in the coming weeks.

VLA2001 is the only inactivated and adjuvanted vaccine against Covid-19 to have received marketing authorization (MA) in Europe for use in primary vaccination in adults aged 18 to 50. VLA2001 is developed on Valneva’s Vero cell-based platform and leverages Valneva’s Japanese encephalitis vaccine production technology, Ixiaro®.


The AOF information reproduced on is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way resist the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity with any use whatsoever of these data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

Leave a Comment